Daily Stock Analysis, AERI, Aerie Pharmaceuticals Inc, priceseries

Aerie Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
39.47
Close
38.83
High
39.52
Low
38.10
Previous Close
39.51
Daily Price Gain
-0.68
YTD High
50.10
YTD High Date
Mar 21, 2019
YTD Low
34.94
YTD Low Date
Jan 2, 2019
YTD Price Change
2.51
YTD Gain
6.91%
52 Week High
74.75
52 Week High Date
Jul 20, 2018
52 Week Low
32.18
52 Week Low Date
Dec 21, 2018
52 Week Price Change
-15.37
52 Week Gain
-28.36%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Oct 10. 2017
55.35
Oct 26. 2017
61.69
12 Trading Days
11.45%
Link
LONG
May 31. 2018
51.30
Jul 2. 2018
65.55
22 Trading Days
27.79%
Link
LONG
Jan 9. 2019
39.84
Feb 6. 2019
45.18
19 Trading Days
13.39%
Link
Company Information
Stock Symbol
AERI
Exchange
NasdaqGM
Company URL
http://www.aeriepharma.com
Company Phone
919-313-9650
CEO
Vicente J. Anido
Headquarters
North Carolina
Business Address
7020 KIT CREEK ROAD, SUITE 270, RESEARCH TRIANGLE PARK, NC 27709
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Major
CIK
0001337553
About

Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which is focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. It product candidates are Rhopressa and Roclatan. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem and Eric J. Toone on June 22, 2005 and is headquartered in Irvine, CA.

Description

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. was founded in 2005 and is based in Irvine, California.